Aptar: 3 Key Takeaways for Long-Term Investors

Aptar reported Q3 2026 core sales growth of 5% across all segments, with Pharma sales up 8% excluding emergency medicine inventory drawdowns and Beauty sales up 8%. However, North American Beauty operations face margin pressures requiring operational improvements. The company recorded a $61.2 million charge after losing administrative control of its Russian subsidiary in September 2026.